Actuate Therapeutics, Inc.

ACTU Healthcare Biotechnology

In the quarter to June 2026, EPS grew 33.3% and free cash flow fell 5.54%, each against the same quarter a year earlier.

0.61 0.11 +22.00%
Market cap
$12.0M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(296.04%) (553.75%) 3,304.93% 2,457.65%
ROA
(150.86%) (190.35%) (321.58%) (336.18%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(217.86%) (280.07%) (567.13%) (2,169.70%)
Free Cash Flow per Share
(0.95) (0.91) (0.83) (0.83)
Free Cash Flow
(20.24) (19.21) (19.60) (19.84)
Other line items

Show all line items

Columns are period end dates